Artículo de opinión
Supervivencia en terapia biológica. ¿Sabemos a qué nos referimos? ¿ Podemos usarla?Drug Survival in Biologic Therapy. Do We Know What it Means? Can We Calculate it?

https://doi.org/10.1016/j.ad.2014.04.004Get rights and content

Section snippets

Conflicto de intereses

J. M. Carrascosa ha recibido honorarios en concepto de conferenciante y asesor y/o ha participado en ensayos clínicos esponsorizados por las siguientes compañías: Merck-Serono, Pfizer, MSD, Abbvie, Centocor, Janssen-Cilag, Novartis, Lilly y Amgen.

J. Notario declara haber recibido honorarios por su colaboración y participación en ensayos clínicos, ponencias y asesoría para Abbvie, Pfizer, Janssen y MSD.

First page preview

First page preview
Click to open first page preview

Bibliografía (16)

There are more references available in the full text version of this article.

Cited by (16)

  • Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit

    2019, Reumatologia Clinica
    Citation Excerpt :

    We have shown, for instance, the case of UST, with no discontinuation for adverse events and ANK with nearly three times the risk of discontinuation than any other biologic agent, independently of the use. In addition, these drugs are used differently for different diseases and so a final treatment dose may be reflecting a temporary cessation due to surgery, or pregnancy, or to remission, according to the different guidelines used by the specialists.7,19–22 The Spanish Rheumatology Society and Hospital Pharmacy Society have developed a joint consensus on the optimization of biologics in patients with RA, AS, and PsA.20

View all citing articles on Scopus
View full text